What Ксидалба Treats: Main Uses and Benefits

Targeting Acute and Severe Skin Infections

This medication is generally used to help with conditions characterized by periods of heightened symptoms, which may include severe bacterial skin and soft tissue infections (ABSSSI). It is applied in clinical settings that involve acute or disruptive symptom patterns, such as cellulitis, abscesses, and wound infections. The medication plays a role in managing symptoms related to the bacterial presence, which is commonly used to help with the acute symptomatic episode.

“The medication is considered relevant for use across domains where additional symptomatic support is needed, and may assist with managing symptoms associated with the functional stress of the infection.”

Relieving Pronounced Symptoms of Infection

Ксидалба is commonly used to help with symptom clusters that may become intense or disruptive associated with these infections, such as spreading redness, swelling, increased warmth, and significant physical discomfort. This is applied in addressing symptoms related to inflammatory or irritative states that create noticeable physiological strain. By managing the infection, the medication provides support that helps ease the overall symptom load, and may assist with maintaining functional stability during symptomatic periods. This supports patients during difficult episodes by easing distress and contributes to improving comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Physical Discomfort

---

Regulatory References

1. European Medicines Agency

Official Eligibility Profile for Ксидалба (Dalbavancin)

Ксидалба (Dalbavancin) is an antibiotic approved by regulatory bodies for use across adults and the full pediatric population (from birth) for its labeled use in skin and skin structure infections.

Eligibility Status	Patient Population Defined by Label
Contraindicated	Patients with known hypersensitivity to dalbavancin (absolute prohibition).
Use Allowed/Established	Adult and pediatric patients (from birth), older adults.
Use Restricted/Conditional	Adult patients with severe chronic renal impairment ( CrCl < 30 mL/min) not on dialysis (requires specific management).
Use with Caution	Patients with moderate or severe hepatic impairment (limited data is available) and those with a history of glycopeptide allergy.
Not Recommended	Pregnant women, unless the benefit clearly outweighs the potential risk (as stated by regulatory authorities).

Pregnancy and Lactation: Use in pregnant women is not recommended by some authorities (e.g., EMA). For nursing mothers, caution is required because it is unknown if the drug is excreted in human milk. Age Restrictions: No restriction exists for its approved indication, as use is established in patients from birth through older adulthood. Organ Function: Use in pediatric patients with severe renal impairment is a use-not-established group as there is insufficient data to recommend a dose adjustment.

Interactions with other medicines and products

Ксидалба (Dalbavancin) has an officially documented interaction profile that is primarily defined by its lack of systemic pharmacokinetic interactions and critical procedural administration restrictions.

Systemic Pharmacokinetic Profile

Official regulatory information indicates that Dalbavancin is not anticipated to cause clinically significant drug-drug interactions via the major metabolic pathways. Dalbavancin is documented as neither a substrate, inhibitor, nor inducer of the major Cytochrome P450 (CYP450) isoenzymes (including CYP3A4, CYP2D6). Consequently, co-administered medicinal products that rely on these enzymes for metabolism are not expected to have their systemic exposure (plasma levels) significantly altered by Dalbavancin. No known interactions with food, alcoholic beverages, or herbal products are documented in the official prescribing information.

Administration-Based Restrictions

The most critical documented restrictions relate to physical incompatibility during administration:

• Prohibited Co-administration: Dalbavancin must not be mixed with other medications or electrolytes or infused simultaneously through the same intravenous line.
• Diluent Restriction: Saline-based infusion solutions (e.g., 0.9% Sodium Chloride) are prohibited for preparation or flushing due to the documented risk of chemical precipitation.
• Flushing Requirement: The shared intravenous line must be cleared with 5% Dextrose Injection, USP to prevent interaction with other substances.

Mechanism of Action: RANKL Inhibition

Ксидалба is a human monoclonal antibody that selectively targets the RANKL signaling pathway. The drug functions as an inhibitor by binding directly to the soluble and transmembrane forms of Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL) with high affinity. This binding event prevents the physiological interaction of RANKL with the RANK receptor located on the surface of osteoclast precursor cells and mature osteoclasts.

The resulting inhibition interrupts the signaling cascade essential for osteoclast formation, function, and survival (osteoclastogenesis). Consequently, the overall number and activity of mature osteoclasts are reduced. This cellular modulation leads to a system-level physiological consequence: a decrease in the rate of bone resorption, thereby limiting the degradation of bone tissue.

Ксидалба (Dalbavancin) is administered solely as an Intravenous (IV) Infusion within a professional clinical setting. The product is supplied as a powder that requires reconstitution and subsequent dilution before it can be administered.

Official Dosing and Frequency

Adult patients with normal renal function have two approved options for the total 1500 mg course:

• Single-Dose Regimen: A single infusion of 1500 mg.
• Two-Dose Regimen: An initial dose of 1000 mg, followed one week later by a second dose of 500 mg.

All doses, regardless of regimen, must be administered over a minimum total infusion time of 30 minutes.

Preparation and Administration

Before administration, the powder must be reconstituted and then further diluted only with 5% Dextrose Injection (D5W). The final diluted solution must have a concentration between 1 mg/mL and 5 mg/mL and must be used within 48 hours of initial reconstitution. The IV line must be flushed with D5W before and after the infusion, and co-infusion with other medications is not permitted.

Population-Specific Adjustments

Specific dose modifications are described for certain groups:

• Renal Impairment: For adults with a creatinine clearance (CrCl) less than 30 mL/min and not on regular hemodialysis, the total course dose is reduced to 1125 mg (e.g., 750 mg followed by 375 mg). No adjustment is needed for patients on regularly scheduled hemodialysis.
• Pediatric Dosing: Doses are calculated based on the child's age and weight, up to a maximum of 1500 mg as a single infusion. No adjustment is specified for older adults (geriatric patients).

This structured approach ensures the product is used in accordance with the established clinical parameters for this medication.

Research evidence / Overview of studies for Ксидалба

---

Evidence for Use in Acute Skin and Skin Structure Infections (ABSSSI)

The research for Dalbavancin was primarily conducted through large-scale, short-term Randomized Controlled Trials (RCTs). These studies were structured to evaluate Dalbavancin against active comparators for serious skin and soft tissue infections. The research examined outcomes related to physical discomfort and systemic or functional imbalance in adult patients who had conditions associated with acute or disruptive episodes, such as cellulitis or major abscesses.

These comparative studies were designed to assess patient status at specific, defined time intervals, with the main focus being on the early clinical response measured between 48 and 72 hours. This measurement was relevant in trials assessing short-term or episodic symptom patterns and monitored changes like the size of the affected area and the presence of fever. The findings describe patterns observed in the studies where the measurements of the early clinical status criteria were reported across the Dalbavancin groups and the active comparator groups at the early assessment point.

Long-Term Studies and Follow-up Durations

The available research provides context but not individual predictions about the durability of the response beyond the short-term treatment phase. The follow-up durations were primarily limited to the intermediate period, assessing outcomes related to systemic or functional imbalance up to approximately 28 days.

While studies monitored responses over these defined time intervals, long-term effects are not fully established. The research provides limited insight into how symptoms evolved in the observed populations well beyond the initial weeks of treatment. Consequently, there is limited information for long-term outcomes or how Dalbavancin may be associated with the prevention of future episodes of heightened symptom activity.

---

Areas of Research Uncertainty and Study Limitations

While a substantial body of evidence exists, the research highlights what is known—and what is still uncertain. Data for certain groups remain insufficient. For instance, the pivotal trials included only a modest number of patients whose infections were specifically caused by MRSA, meaning the research provides limited insight into this specific bacterial type. Furthermore, the patient groups in the main comparative studies typically excluded patients who had recently been treated with other Gram-positive antibiotics. Certainty remains low for long-term clinical and functional measures because the follow-up durations were limited in the initial, highest-quality studies.

Key Studies & References DALVANCE (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients (Press Release summarizing pediatric trial DUR001-306)

Common questions about Ксидалба (FAQ)

---

Q: Does Ксидалба interact with common pain relievers like ibuprofen or acetaminophen?

Regulatory documents indicate that Ксидалба is not anticipated to cause clinically significant drug-drug interactions, as it does not heavily interfere with the major enzyme systems (CYP450) that process many other medicines in the body. Due to this profile, the drug is not generally expected to alter the metabolism of many co-administered medicines, including common pain relievers.

---

Q: Are there known interactions between Ксидалба and birth control pills?

Official information indicates that Ксидалба is not associated with inhibiting or inducing the major enzymes that break down other medicines. Consequently, it is not anticipated that the drug would significantly alter the systemic exposure of co-administered medicines, such as hormonal contraceptives.

---

Q: Do the official guidelines mention any risk to the liver from Ксидалба?

Official documents note that elevations in certain liver enzyme laboratory values, specifically GGT and ALT, were reported as adverse reactions in clinical trials. Official prescribing information notes that specific consideration is required for patients who have moderate or severe hepatic (liver) impairment.

---

Q: How long does the main benefit of one dose of Ксидалба typically last?

The drug is characterized by an extended presence in the body, with a long half-life of several days. This prolonged presence allows the antibacterial effect to be sustained for an extended period, a characteristic that supports the use of a single-dose or a limited two-dose regimen.

---

Q: Is it possible for an infection to become resistant to Ксидалба over time?

Official labels contain a warning related to the potential for the development of drug-resistant bacteria with antibacterial agents. For this reason, official information states that the drug is indicated only when an infection is proven or strongly suspected to be caused by susceptible bacteria.

---

Q: What is the brand name and what is the generic name for Ксидалба?

The generic, or chemical, name for this medicine is dalbavancin. While the original trade name used in this context is Ксидалба, the drug is also known by the trade name DALVANCE in the United States.

---

Q: How does Ксидалба compare to similar, older medications in the same drug class?

Regulatory review documents describe Ксидалба as a second-generation lipoglycopeptide. These documents note that the drug possesses different characteristics compared to classical glycopeptides, including a long half-life and a pharmacokinetic profile that allows for infrequent dosing.

---

Q: Why would a doctor choose Ксидалба over a different antibiotic?

Regulatory information highlights that the drug's extended half-life and limited dosing course can simplify the therapeutic approach. This characteristic supports its use in various clinical settings and may offer administrative convenience, as it reduces the need for continuous intravenous therapy.

---

Q: Is it normal to feel tired or dizzy after receiving Ксидалба?

Official safety data lists dizziness and difficulty sleeping (insomnia) as uncommon adverse reactions, meaning they may affect up to 1 in 100 people. The regulatory documents do not list tiredness or fatigue within the common or uncommon frequency groups for this drug.

---

Q: What type of infections is Ксидалба not designed to treat?

The drug is indicated only for the treatment of infections caused by designated susceptible Gram-positive microorganisms. It is not intended to treat infections caused by Gram-negative bacteria, fungi, or viruses, which require different types of anti-infective agents.

---

Q: Are there different forms or concentrations of Ксидалба available?

Ксидалба is supplied only as a sterile powder for solution in single-use vials, each containing an amount equivalent to 500 mg of the active ingredient. There are no other dosage forms, such as oral tablets or capsules, available.

---

Q: Does Ксидалба have a black box warning from regulatory agencies?

The official US prescribing information does not contain a Black Box Warning (also called a Boxed Warning), which is reserved for the most serious safety issues. Major warnings and precautions are instead detailed in a separate section of the regulatory label.

---

Q: What kind of monitoring is typically done while a person is on Ксидалба?

Official information emphasizes that due to the risk of serious hypersensitivity or infusion-related reactions, patients must be carefully monitored during and immediately following the infusion. This requirement is a standard precaution in the administration instructions.

---

Q: Is there any information on how Ксидалба affects mental clarity or focus?

While the regulatory safety profile does not directly list effects on mental clarity or focus, it does list central nervous system effects such as dizziness and insomnia as uncommon adverse reactions, as listed in the adverse reactions section.

---

Q: What evidence supports the use of Ксидалба in hospital settings?

The drug is generally administered in a professional clinical setting. The single-dose option and long half-life characteristic is relevant for flexible use across professional clinical settings, including both inpatient and outpatient settings.

---

Q: Are there any long-term effects that have been studied after using Ксидалба?

Regulatory review documents explicitly state that long-term studies were not conducted (for instance, to assess lifetime cancer risk). The follow-up period in the main clinical trials was limited to an intermediate period of approximately 28 days.

---

Q: Is there a patient information leaflet (PIL) available for Ксидалба online?

Yes, regulatory bodies like the European Medicines Agency (EMA) and similar national health agencies publish a comprehensive Patient Information Leaflet (PIL) or package insert. This document contains detailed information written for the patient and is generally available online.

Storage and Disposal Information

The storage requirements for Ксидалба (Dalbavancin) are defined by the product's state (unopened powder vs. prepared solution) and must adhere strictly to regulatory labeling to maintain stability.

Storage Conditions

Product State	Temperature Requirement
Unopened Powder	Store at controlled room temperature, 20°C to 25°C (68°F to 77°F).
Prepared Solution	Store at 2°C to 8°C (refrigerated) or 20°C to 25°C (room temperature).

Crucially, do not freeze the product in any form. The drug must also be stored in the original container, and it is a mandatory requirement to keep out of the sight and reach of children.

Stability and Disposal

The total time from the initial mixing (reconstitution) of the powder to the end of the infusion must not exceed 48 hours. Any unused portion of the prepared solution must be discarded. Official disposal protocols state that medicines must not be thrown away via wastewater or household waste, and disposal must follow local requirements.